ArticleBMC cancer2018
A quantitative multimodal metabolomic assay for colorectal cancer.
Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Colorectal neoplasia-specific amino acid profiles and their diagnostic potential: a systematic review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Pooled it
- The Utility of Lipidomic Analysis in Colorectal Cancer Diagnosis and Prognosis-A Systematic Review of Recent Literature.International journal of molecular sciences · 2024Pooled it
- An Integrative Approach Using Molecular and Metabolomic Studies Reveals the Connection of Glutamic Acid with Telomerase and Oxidative Stress in Berberine-Treated Colorectal Cancer Cell Line HCT 116.Applied biochemistry and biotechnology · 2025Article
- Metabolomic Exploration of Colorectal Cancer Through Amino Acids and Acylcarnitines Profiling of Serum Samples.Cancers · 2025Article
- Integrating multi-omics and machine learning methods reveals the metabolism of amino acids and derivatives-related signature in colorectal cancer.Frontiers in oncology · 2025Article
- Pathophysiological roles of the serum acylcarnitine level and acylcarnitine/free carnitine ratio in patients with cardiovascular diseases.International journal of cardiology. Heart & vasculature · 2024Article
- Secretion of Sphinganine by Drug-Induced Cancer Cells and Modified Mimetic Sphinganine (MMS) as c-Src Kinase Inhibitor.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Profiling the metabolic disorder and detection of colorectal cancer based on targeted amino acids metabolomics.Journal of translational medicine · 2023Article
- Paired microbiome and metabolome analyses associate bile acid changes with colorectal cancer progression.Cell reports · 2023Article
- Targeted O-glycoproteomics for the development of diagnostic markers for advanced colorectal cancer.Frontiers in oncology · 2023Article
- High-throughput quantitation of amino acids and acylcarnitine in cerebrospinal fluid: identification of PCNSL biomarkers and potential metabolic messengers.Frontiers in molecular biosciences · 2023Article
- Plasma metabolomic profiles for colorectal cancer precursors in women.European journal of epidemiology · 2022Article
- Biomarkers to Detect Early-Stage Colorectal Cancer.Biomedicines · 2022Review
- Lipidomic Signatures for Colorectal Cancer Diagnosis and Progression Using UPLC-QTOF-ESIBiomolecules · 2021Article
- Review
- Uterine Metabolomics Reveals Protection of Taohong Siwu Decoction Against Abnormal Uterine Bleeding.Frontiers in pharmacology · 2020Article
- Evodiamine inhibits migration and invasion by Sirt1-mediated post-translational modulations in colorectal cancer.Anti-cancer drugs · 2019Article
- A non-invasive approach to explore the discriminatory potential of the urinary volatilome of invasive ductal carcinoma of the breast.RSC advances · 2018Article
- Microbial markers in colorectal cancer detection and/or prognosis.World journal of gastroenterology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundEarly diagnosis of colorectal cancer (CRC) simplifies treatment and improves treatment outcomes. We previously described a diagnostic metabolomic biomarker derived from semi-quantitative gas chromatography-mass spectrometry. Our objective was to determine whether a quantitative assay of additional metabolomic features, including parts of the lipidome could enhance diagnostic power; and whether there was an advantage to deriving a combined diagnostic signature with a broader metabolomic representation.
methodsThe well-characterized Biocrates P150 kit was used to quantify 163 metabolites in patients with CRC (N = 62), adenoma (N = 31), and age- and gender-matched disease-free controls (N = 81). Metabolites included in the analysis included phosphatidylcholines, sphingomyelins, acylcarnitines, and amino acids. Using a training set of 32 CRC and 21 disease-free controls, a multivariate metabolomic orthogonal partial least squares (OPLS) classifier was developed. An independent set of 28 CRC and 20 matched healthy controls was used for validation. Features characterizing 31 colorectal adenomas from their healthy matched controls were also explored, and a multivariate OPLS classifier for colorectal adenoma could be proposed.
resultsThe metabolomic profile that distinguished CRC from controls consisted of 48 metabolites (R
conclusionThe diagnostic power for metabolomic tests for colorectal neoplasia can be improved by utilizing a multimodal approach and combining metabolites from diverse chemical classes. In addition, quantification of metabolites enhances separation of disease-specific metabolomic profiles. Our future efforts will be focused on developing a quantitative assay for the metabolites comprising the optimal diagnostic biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.